- CA$0.44m
- -CA$0.03m
Brief: Vaxil Initiates Pre-Clinical Study In New Oncology Target
Brief: Vaxil Bio Grants 1.4 Mln Stock Options In Aggregate To CEO And CFO
Brief: Vaxil Announces Positive Results On CorVax In Vivo Study
Brief: Vaxil Provides Update On In Vivo Study
Brief: Vaxil Bio Ltd Commences In Vivo (Animal) Study For Covid-19 Vaccine Candidate
Brief: Vaxil Announces Private Placement Extension
Brief: Vaxil Announces Brokered Private Placement
Brief: Vaxil Bio Announces Collaboration Agreement With The Tel Aviv Sourasky Medical Center
Brief: Vaxil Bio - Not Making Claims That It Has Developed Vaccine For COVID-19
Brief: Vaxil Commences Preclinical COVID-19 Vaccine Trial And Files An Additional COVID-19 Patent
Brief: Vaxil Announces Closing Of Bridge Financing And Provides Update On Corona Virus Vaccine Work
Brief: Vaxil Says Will Continue To Pursue Convertible Debt Financing With Amended Terms
Brief: Vaxil Provides Further Information On Possible Identification Of Corona Virus Vaccine
Brief: Vaxil Announces Identification Of A Potential Coronavirus Vaccine
Brief: BGN Technologies Licenses Polymer For Targeted Cancer Therapy To Vaxil Bio
Brief: Vaxil Appoints CEO David Goren as New Chairman
Brief: Vaxil Appoints Veteran Pharma Executive David Goren As CEO
Brief: Vaxil Obtains U.S. Patent For Signal Peptide Antibody Platform
Brief: Vaxil Completes Oversubscribed Financing To Advance Cancer Immunotherapy Research